Xintian Qin

机构：First Affiliated Hospital of Guangdong Pharmaceutical University

发表论文 14 篇 · 总被引 181 次 · h-index 8

代表论文

• Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study (2024 · Journal of Clinical Oncology · 被引 36)
• Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial (2023 · Signal Transduction and Targeted Therapy · 被引 32)
• Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study (2024 · Oral Oncology · 被引 25)
• Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study (2022 · The Lancet Regional Health - Western Pacific · 被引 23)
• Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China (2025 · The Lancet · 被引 18)
• Detection of nasopharyngeal carcinoma susceptibility with single nucleotide polymorphism analysis using next-generation sequencing technology (2017 · Oncotarget · 被引 17)